SCF-ECCA-SEP-TEMP-0004
Temporal Windows of Sepsis-Associated Encephalopathy (SAE)
SCF Multi-Neurosystems Shock State (MNSS) Atlas
Pre-Sepsis → Sepsis → Septic Encephalopathy → Recovery Mapping
Integrated Neuroimmune, Neurocardiac, Neurovascular, Neurometabolic, Neuroendocrine, Neuroglial, Neuroaxonal, Glymphatic, and Connectomic Biomarker Framework
⸻
I. SCF SEPTIC ENCEPHALOPATHY TEMPORAL MODEL
Sepsis-associated encephalopathy (SAE) represents one of the most rapidly evolving Multi-Neurosystems Shock States.
Within the SCF framework, SAE progression follows:
Phase A
Pre-Sepsis Homeostasis
↓
Phase B
Systemic Infection Priming
↓
Phase C
Early Septic Neuroimmune Activation
↓
Phase D
Pre-Encephalopathic Septic Brain Injury
↓
Phase E
Early Septic Encephalopathy
↓
Phase F
Established Septic Encephalopathy
↓
Phase G
Acute Multi-Neurosystems Shock
↓
Phase H
Shock Resolution
↓
Phase I
Connectomic Reconstruction
↓
Phase J
Post-Septic Neurocognitive Syndrome
⸻
II. PHASE A — PRE-SEPSIS HOMEOSTASIS
SCF Classification
MNSS-0
⸻
Temporal Window
Weeks–Years Before Infection
⸻
Functional State
Normal compensation
⸻
Biomarker Panel
Neuroimmune
Biomarker | Baseline |
IL-6 | <2 pg/mL |
TNF-α | <5 pg/mL |
IL-1β | <1 pg/mL |
HMGB1 | Low |
Neurocardiac
Biomarker | Baseline |
SDNN | >100 ms |
RMSSD | >30 ms |
Troponin | Normal |
Neurovascular
Biomarker | Baseline |
MMP-9 | <150 ng/mL |
S100B | <0.1 ng/mL |
Ang-2 | Normal |
Neurometabolic
Biomarker | Baseline |
Lactate | <2 mmol/L |
ATP Production | Normal |
Neuroendocrine
Biomarker | Baseline |
Cortisol Rhythm | Normal |
ACTH | Normal |
⸻
Therapeutic Window
Maximum prevention potential
⸻
III. PHASE B — SYSTEMIC INFECTION PRIMING
SCF Classification
MNSS-IA
⸻
Temporal Window
Hours–Days After Infection
⸻
Dominant Shock State
Systemic Inflammatory Activation
⸻
Neuroimmune Shock
Biomarker | Change |
CRP | ↑ |
PCT | ↑ |
IL-6 | ↑ |
TNF-α | ↑ |
IL-8 | ↑ |
⸻
Neurocardiac Shock
Biomarker | Change |
SDNN | ↓10% |
RMSSD | ↓ |
LF/HF Ratio | ↑ |
⸻
Neurovascular Shock
Biomarker | Change |
Ang-2 | ↑ |
vWF | ↑ |
ICAM-1 | ↑ |
⸻
Neurometabolic Shock
Biomarker | Change |
Lactate | Mild ↑ |
Lactate/Pyruvate Ratio | ↑ |
⸻
Clinical Symptoms
- Malaise
- Fever
- Tachycardia
- Reduced sleep quality
⸻
Reversibility
Very High
⸻
IV. PHASE C — EARLY SEPTIC NEUROIMMUNE ACTIVATION
SCF Classification
MNSS-IB
⸻
Temporal Window
24–48 Hours
⸻
Dominant Shock State
Neuroimmune-Cytokine Propagation
⸻
Neuroimmune Biomarkers
Biomarker | Change |
IL-6 | ↑↑ |
TNF-α | ↑↑ |
IL-1β | ↑ |
HMGB1 | ↑ |
CXCL10 | ↑ |
⸻
Neurovascular Biomarkers
Biomarker | Change |
Ang-2 | ↑↑ |
Syndecan-1 | ↑ |
MMP-9 | ↑ |
⸻
Neurocardiac Biomarkers
Biomarker | Change |
SDNN | ↓15–20% |
RMSSD | ↓ |
⸻
Neuroendocrine Biomarkers
Biomarker | Change |
Cortisol | ↑ |
ACTH | ↑ |
Vasopressin | ↑ |
⸻
Early Symptoms
- Brain fog
- Mild attention deficits
- Fatigue
- Sleep disruption
⸻
Therapeutic Window
Highest-value neuroprotection window
⸻
V. PHASE D — PRE-ENCEPHALOPATHIC SEPTIC BRAIN INJURY
SCF Classification
MNSS-II
⸻
Temporal Window
24–72 Hours Before Delirium
⸻
Dominant Shock State
Neurovascular-Neuroglial Coupling Failure
⸻
Neurovascular Shock
Biomarker | Change |
MMP-9 | ↑↑ |
S100B | ↑ |
Claudin-5 Fragments | ↑ |
Occludin Fragments | ↑ |
⸻
Neuroglial Shock
Biomarker | Change |
GFAP | ↑ |
YKL-40 | ↑ |
sTREM2 | ↑ |
⸻
Neurometabolic Shock
Biomarker | Change |
Lactate | 2–4 mmol/L |
cf-mtDNA | ↑ |
ATP Production | ↓20–30% |
⸻
Clinical Features
- Fluctuating cognition
- Delayed processing
- Sleep-wake inversion
⸻
Reversibility
High
⸻
VI. PHASE E — EARLY SEPTIC ENCEPHALOPATHY
SCF Classification
MNSS-IIIA
⸻
Temporal Window
Hours–Days After Delirium Onset
⸻
Dominant Shock State
Neuroglial Shock
⸻
Neuroglial Injury
Biomarker | Change |
GFAP | ↑↑ |
S100B | ↑↑ |
YKL-40 | ↑↑ |
⸻
Neuroimmune Injury
Biomarker | Change |
IL-6 | ↑↑↑ |
TNF-α | ↑↑ |
HMGB1 | ↑↑ |
⸻
Connectomic Biomarkers
Biomarker | Change |
EEG Delta | ↑ |
EEG Theta | ↑ |
qEEG Connectivity | ↓ |
⸻
Clinical Features
- Delirium
- Inattention
- Confusion
- Agitation or hypoactivity
⸻
VII. PHASE F — ESTABLISHED SEPTIC ENCEPHALOPATHY
SCF Classification
MNSS-IIIB
⸻
Temporal Window
Days–Weeks
⸻
Dominant Shock State
Neuroaxonal Shock
⸻
Neuroaxonal Biomarkers
Biomarker | Change |
NfL | ↑ |
UCH-L1 | ↑ |
NSE | ↑ |
Total Tau | ↑ |
⸻
Neurovascular Biomarkers
Biomarker | Change |
Ang-2 | ↑↑ |
vWF | ↑↑ |
Syndecan-1 | ↑↑ |
⸻
Neurocardiac Biomarkers
Biomarker | Change |
SDNN | <80 ms |
RMSSD | ↓↓ |
Troponin | Mild ↑ |
⸻
Clinical Features
- Persistent delirium
- Executive dysfunction
- Autonomic instability
⸻
Reversibility
Moderate
⸻
VIII. PHASE G — ACUTE MULTI-NEUROSYSTEMS SHOCK
SCF Classification
MNSS-IV
⸻
Temporal Window
Hours–Days
⸻
Dominant Shock State
Global Septic Connectomic Collapse
⸻
Neuroimmune Peak
- IL-6
- TNF-α
- HMGB1
- IL-8
⸻
Neurovascular Peak
- Ang-2
- Syndecan-1
- MMP-9
- S100B
⸻
Neuroglial Peak
- GFAP
- YKL-40
- sTREM2
⸻
Neuroaxonal Peak
- NfL
- UCH-L1
- NSE
- Tau
⸻
Neurocardiac Peak
Biomarker | Status |
SDNN | <50 ms |
RMSSD | Severely reduced |
Troponin | Elevated |
NT-proBNP | Elevated |
⸻
Neurometabolic Peak
Biomarker | Status |
Lactate | >4–5 mmol/L |
cf-mtDNA | Peak |
ATP Production | ↓50–70% |
⸻
Clinical Features
- Severe encephalopathy
- Coma
- Septic shock
- Seizures
- Respiratory failure
⸻
Reversibility
Limited
Highest mortality risk
⸻
IX. PHASE H — SHOCK RESOLUTION
SCF Classification
MNSS-R1
⸻
Temporal Window
Days–Weeks
⸻
Biomarker Trends
Biomarker | Trend |
CRP | ↓ |
PCT | ↓ |
IL-6 | ↓ |
TNF-α | ↓ |
Lactate | ↓ |
Ang-2 | ↓ |
⸻
Clinical Features
- Delirium improvement
- Improved arousal
- Reduced vasopressor requirements
⸻
Therapeutic Window
Highest restorative potential
⸻
X. PHASE I — CONNECTOMIC RECONSTRUCTION
SCF Classification
MNSS-R2
⸻
Temporal Window
Weeks–Months
⸻
Recovery Biomarkers
Biomarker | Trend |
GFAP | ↓ |
NfL | ↓ |
qEEG Connectivity | ↑ |
DTI FA | ↑ |
HRV SDNN | ↑ |
Cortisol Rhythm | Restored |
⸻
Clinical Features
- Cognitive improvement
- Executive recovery
- Improved autonomic function
⸻
XI. PHASE J — POST-SEPTIC NEUROCOGNITIVE SYNDROME
SCF Classification
MNSS-R3
⸻
Temporal Window
Months–Years
⸻
Residual Injury Biomarkers
Neuroimmune
- IL-6 (persistent low-grade elevation)
- YKL-40
- HMGB1
Neuroglial
- GFAP
- sTREM2
Neuroaxonal
- NfL
- Tau
Neurocardiac
- Persistent HRV suppression
Neuroendocrine
- Cortisol rhythm abnormalities
Connectomic
- Persistent qEEG dysconnectivity
- Reduced DMN integrity
⸻
Clinical Manifestations
- Post-sepsis cognitive impairment
- Executive dysfunction
- Fatigue
- Sleep disorders
- Dysautonomia
- Depression/anxiety
⸻
XII. MASTER SCF PRE/POST SEPTIC ENCEPHALOPATHY BIOMARKER PANEL
Stage | Neuroimmune | Neurocardiac | Neurovascular | Neurometabolic | Neuroendocrine | Neuroglial | Neuroaxonal |
Pre-Sepsis | IL-6, TNF-α | HRV | MMP-9 | Lactate | Cortisol | GFAP | NfL |
Infection Priming | CRP, PCT | SDNN↓ | Ang-2↑ | L/P Ratio↑ | ACTH↑ | YKL-40↑ | Stable |
Early Neuroimmune Activation | HMGB1↑ | LF/HF↑ | Syndecan-1↑ | cf-mtDNA↑ | Vasopressin↑ | GFAP↑ | Stable |
Pre-Encephalopathy | IL-6↑↑ | HRV↓↓ | S100B↑ | ATP↓ | Cortisol↑ | GFAP↑ | Mild NfL↑ |
Early SAE | Cytokine Surge | SDNN↓ | BBB Injury | Lactate↑ | HPA Activation | GFAP↑↑ | NfL↑ |
Established SAE | Persistent Cytokines | Troponin↑ | Endotheliopathy | Mitochondrial Failure | Circadian Loss | YKL-40↑↑ | UCH-L1↑ |
Acute Shock | Peak Cytokines | Severe HRV Collapse | Peak BBB Injury | Peak Lactate | HPA Collapse | Peak GFAP | Peak NfL |
Recovery | Cytokines↓ | HRV↑ | Endothelial Repair | ATP Recovery | Rhythm Restoration | GFAP↓ | NfL↓ |
Reconstruction | HMGB1↓ | SDNN↑ | MMP-9↓ | Bioenergetic Recovery | Normalized Cortisol | sTREM2↓ | Tau↓ |
⸻
XIII. SEPTIC ENCEPHALOPATHY THERAPEUTIC TEMPORAL WINDOW MATRIX
Window | SCF Phase | Reversibility | Primary Therapeutic Objective |
Window 1 | MNSS-IA | Very High | Infection control before neuroinvasion |
Window 2 | MNSS-IB | Very High | Suppress neuroimmune propagation |
Window 3 | MNSS-II | High | Preserve BBB and glial integrity |
Window 4 | MNSS-IIIA | High | Prevent neuroaxonal injury |
Window 5 | MNSS-IIIB | Moderate | Stabilize connectomic dysfunction |
Window 6 | MNSS-IV | Limited | Preserve life and organ function |
Window 7 | MNSS-R1 | High | Accelerate shock resolution |
Window 8 | MNSS-R2 | Moderate-High | Promote connectomic reconstruction |
Window 9 | MNSS-R3 | Variable | Prevent chronic neurocognitive disability |
⸻
XIV. SCF EARLIEST PREDICTIVE BIOMARKER PANEL FOR SAE
The earliest measurable indicators preceding overt septic encephalopathy are:
- IL-6
- Procalcitonin (PCT)
- HMGB1
- Angiopoietin-2 (Ang-2)
- Syndecan-1
- HRV SDNN decline
- Lactate/Pyruvate Ratio
- cf-mtDNA
- GFAP
- YKL-40
These biomarkers define the highest-yield predictive and intervention window prior to development of overt delirium and septic encephalopathy.
MASTER REGISTRY INDEX
- SCF-ECCA-SEP-TEMP-0004 — Septic Encephalopathy Temporal Window Atlas
- SCF-MNSS-0001 — Multi-Neurosystems Shock State Framework
- SCF-ECCA-SEP-0001 — Septic Encephalopathy Module
- SCF-ECCA-SEP-BIO-0005 — Septic Encephalopathy Biomarker Panel
- SCF-CONNECTOMIC-RECONSTRUCTION-0001 — Neuroimmune Connectomic Reconstruction Framework
- SCF-BIOMARKER-ENDPOINTS-0001 — Biomarker Endpoint Validation Framework
- SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol
- SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema